Table 1

 Demographic and clinical characteristic of patients included in the study

Total patients(n = 132)Infliximab(n = 63)Etanercept(n = 35)Adalimumab(n = 34)
DAS 28, disease activity score including 28 joint counts; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire.
Where applicable, the values are expressed as mean (SD).
*126 patients evaluable for clinical response.
Age (years)57.28 (12.46)59.12 (10.86)58.4 (11.99)52.57 (14.87)
Female/male101/3146/1728/727/7
Disease duration (years)8.3 (6.93)9.08 (8.11)6.15 (4.72)9.58 (6.65)
Tender joints (68)15.96 (9.9)18.1 (10.3)16.65 (9.7)11.03 (7.36)
Swollen joints (66)9.59 (5.7)7.9 (4.88)13.17 (7.46)9.36 (3.21)
Erosions (%)100100100100
DAS 285.87 (0.99)5.93 (1.08)5.95 (1.08)5.52 (0.7)
HAQ1.598 (0.69)1.73 (0.57)1.74 (0.77)1.11 (0.66)
Responders (%)*66616576
Previous DMARDs, n of patients (%)
    Methotrexate131 (99.24)63 (100)34 (97.14)34 (100)
    Hydroxycloroquine93 (70.45)53 (84.12)22 (62.85)19 (55.88)
    Sulfasalazine61 (46.21)32 (50.79)16 (47.71)13 (38.23)
    Ciclosporin A48 (36.36)29 (46.03)12 (34.28)7 (20.58)
    Others34 (25.75)14 (22.22)9 (25.71)11 (32.35)
DMARDs associated, n of patients (%)
    Methotrexate115 (87.12)63 (100)29 (82.85)23 (67.64)
    Leflunomide2 (1.51)002 (5.88)
    None15 (11.36)06 (17.14)9 (26.47)